TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03260322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8374
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: intravenous
Study: NCT04272151

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCMA CAR-T cells
Description: A single infusion of BCMA CAR-T cells will be administered intravenously.
Study: NCT03934684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Carfilzomib + Dexamethasone
Description: Drug: Carfilzomib + Dexamethasone~* Carfilzomib will be administered as a 30-minute infusion.~* Dexamethasone will be taken by mouth or intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: Carfilzomib + Lenalidomide + Dexamethasone
Description: Drug: Carfilzomib + Lenalidomide + Dexamethasone~* Carfilzomib will be administered as a 10 minute infusion.~* Lenalidomide will be taken orally.~* Dexamethasone will be taken by mouth or intravenously.
Study: NCT02236013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral
Study: NCT03906747

Intervention type: OTHER
Intervention: Interviews, questionnaire and focused group discussions
Description: To determine the effectiveness of the quality of care as perceived by relatives, we will perform a survey during the ED stay, with the next-of-kin to patients who was on the EOL pathway using a questionnaire developed for ED settings. The questionnaire will be administered by the research assistant face-to-face in the emergency department to assess the quality of care and the level of support provided to patients and their families in the last days of life.~We will also determine the level of staff's knowledge and perception of the EOL care using a locally-designed self-administered anonymous survey.~A focus group discussion (FGD) will be formed in each hospital to identify the gaps to the current EOL care by structured questionnaire. The group will also make recommendations to improve the quality of the EOL care. There will be separate FGD for: (i) healthcare professionals (ii) family members and (iii) general practitioners who will care for the patient if terminally discharged.

Intervention type: OTHER
Intervention: Interviews, questionnaire and focused group discussions
Description: To determine the effectiveness of the quality of care as perceived by relatives, we will perform a survey during the ED stay, with the next-of-kin to patients who was on the EOL pathway using a questionnaire developed for ED settings. The questionnaire will be administered by the research assistant face-to-face in the emergency department to assess the quality of care and the level of support provided to patients and their families in the last days of life.~We will also determine the level of staff's knowledge and perception of the EOL care using a locally-designed self-administered anonymous survey.~A focus group discussion (FGD) will be formed in each hospital to identify the gaps to the current EOL care by structured questionnaire. The group will also make recommendations to improve the quality of the EOL care. There will be separate FGD for: (i) healthcare professionals (ii) family members and (iii) general practitioners who will care for the patient if terminally discharged.

Intervention type: OTHER
Intervention: Review of medical records
Description: Electronic medical records will be reviewed to collect the following data:~1. Proportion of patients who fits criteria of EOL who died within 48 hours;~2. Proportion of patients on EOL pathway who have documentation that patient and/or family are given opportunities to discuss an individualised care plan;~3. Proportion of patients on EOL pathway who have documentation of an individualised care plan that is followed;~4. Proportion of patients on EOL pathway who have symptoms who are prescribed with medicines with individualised indications for use, dosage and route of administration
Study: NCT00819234

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo pramlintide and placebo metreleptin twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide and Metreleptin
Description: Subcutaneous injection, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide and Metreleptin
Description: Subcutaneous injection, twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide and Metreleptin
Description: Subcutaneous injection, twice daily
Study: NCT01258361

Intervention type: PROCEDURE
Intervention: echocardiography
Description: Echocardiography is performed for all patients
Study: NCT03174938

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Flutemetamol F18 Injection
Description: PET imaging of Abeta amyloid

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Flutemetamol F18 Injection
Description: PET imaging of Abeta amyloid

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Flutemetamol F18 Injection
Description: PET imaging of Abeta amyloid

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-RO6958948
Description: PET imaging of Tau aggregates

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-RO6958948
Description: PET imaging of Tau aggregates

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-RO6958948
Description: PET imaging of Tau aggregates

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-RO6958948
Description: PET imaging of Tau aggregates
Study: NCT02572609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mucosolvan ® adult syrup
Study: NCT02095067

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Video consultation
Study: NCT02372240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VLX1570 and dexamethasone
Study: NCT01365065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 400mg (4 x 100mg) orally daily for 14 days
Study: NCT00036296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: talampanel
Description: 75mg per day divided into 3 doses for 22 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: talampanel
Description: 75mg per day divided into 3 doses for 22 days
Study: NCT04398251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Febuxostat 40mg Tab
Description: For the uric acid control group, except that lifestyle changes were the same as those in the uric acid non-drug control group, non-drug uric acid control group was given febuxostat to reduce uric acid synthesis. Febuxostat is taken at a dose of 40 mg three times a week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-drug control group
Description: All patients in the group are advised to live regularly after operation, drink plenty of water, drink more than 2000ml every day, reduce the intake of high purine food and fructose-rich beverages, increase the intake of fresh vegetables, control weight and exercise regularly
Study: NCT03784417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EUS-guided laser ablation
Description: EUS-guided LA will be performed with an endoscopic ultrasound guided approach using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge flexible needle that is inserted in the working channel of the echoendoscope.
Study: NCT03174938

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: [18F]-RO6958948
Description: PET imaging of Tau aggregates

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Elecsys (Roche) Abeta42, Ttau and Ptau
Description: Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
Study: NCT03652376

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benralizumab
Description: Treatment with Benralizumab 30 mg s.c. every 4 weeks (three times)
Study: NCT03053583

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope blade
Description: The POGO score assesses the percent of the glottic opening that can be seen with each blade

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope blade
Description: The POGO score assesses the percent of the glottic opening that can be seen with each blade

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscope blade
Description: The POGO score assesses the percent of the glottic opening that can be seen with each blade
Study: NCT04112888

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Collagen
Description: Patients will receive 3 to 5 collagen infiltrations in the scar once per week. Patients with episiotomy will receive 3 collagen infiltrations while patients who underwent a cesarean section will receive 5 collagen infiltrations. The infiltration will be done by tunneling technique, that is, it will be applied along the scar, placing the needle almost tangential to the entire length of the area, then it will be injected and at the same time the needle will be removed. Infiltrations will be carried out intradermally, previously performing asepsis in the area to be infiltrated. 2 ml syringes will be used to infiltrate the episiotomy scars (we will use 1 vial of 2 ml ) and 5 ml for cesarean scars (2 vials of 2 ml ) and sterile needles of 30G, 13mm.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rehabilitation sessions
Description: Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. There will be two sessions per week for four weeks. The sessions will last 45 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation sessions
Description: Patients will receive the conventional treatment of 8 rehabilitation sessions with massage therapy techniques, muscle stretches and fascial work. The rehabilitation sessions will always be carried out by the same physiotherapist specialized in pelvic floor. There will be two sessions per week for four weeks. The sessions will last 45 minutes.
Study: NCT03975062

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: 150 mg twice daily (BID)
Study: NCT03174938

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Elecsys (Roche) Abeta42, Ttau and Ptau
Description: Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Elecsys (Roche) Abeta42, Ttau and Ptau
Description: Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Elecsys (Roche) Abeta42, Ttau and Ptau
Description: Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Elecsys (Roche) Abeta42, Ttau and Ptau
Description: Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
Study: NCT03975062

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dabigatran etexilate
Description: 150 mg twice daily (BID)
Study: NCT04020328

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leflunomide 20 mg+prednisone 0.5mg/kg/d
Description: Leflunomide plus low dose glucocorticoids to have the immunosuppressive therapy to those progressive IgA nephropathy with eGFR\<50ml/min
Study: NCT01822496

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: 30 once-daily 2 Gy fractions over 6 weeks totaling 60 Gy of intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3D-CRT).
Study: NCT03174938

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
Description: Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
Description: Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
Description: Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
Description: Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Lumipulse (Fujirebio) Abeta42, Ttau and Ptau
Description: Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
Study: NCT03805958

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: realtime ultrasonography
Description: Applying realtime ultrasound during the combined anesthesia

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prescan ultrasonography
Description: Applying realtime ultrasound before the combined anesthesia
Study: NCT04560361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment
Description: Continue the electroacupuncture treatment as described above for 30 minutes.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture treatment
Description: Continue the sham electroacupuncture treatment as described above for 30 minutes.
Study: NCT05437471

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNRH Analoge, Duphaston, Letrozole
Description: GNRH Analoge, Duphaston, Letrozole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GNRH Analoge, Duphaston, Letrozole
Description: GNRH Analoge, Duphaston, Letrozole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GNRH Analoge, Duphaston, Letrozole
Description: GNRH Analoge, Duphaston, Letrozole
Study: NCT02646046

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combi lone-CPR
Description: When study participants meet the arrest victim (simulated), they start chest compression and call for help to EMS at the same time, then continue the chest compression and 2 breath alternatively until the EMS arrival

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional lone-CPR
Description: When study participants meet the arrest victim (simulated), they first call for help to EMS and then start chest compression and 2 breath alternatively until the EMS arrival
Study: NCT01237392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact ultrasonic debridement device
Description: Cavitational ultrasound wound debridement device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact ultrasonic debridement device
Description: Cavitational ultrasound wound debridement device
Study: NCT01388543

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atazanavir
Description: Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days
Study: NCT00630864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fx-1006A
Description: During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
Study: NCT01113229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: two misoprostol tablets taken orally (400µg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Misoprostol
Description: two misoprostol tablets taken orally (400µg)
Study: NCT04458038

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: driving simulator
Description: For this study a driving simulator is being used which is an internationally approved method. Besides the driving simulator following tests are done: COPD Assessment Test (CAT), Hospital Anxiety and Depression Scale (HADS), Montreal Cognitive Assessment (MoCA), a clock drawing test and a continuous reaction time test (CRT). A CardioRespiratory Monitor (CRM), NOX T3TM, is used to measure if the patients have moderate to severe OSA. Furthermore, following tests are done: Epworth Sleepiness Scale (ESS).
Study: NCT00806338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trodusquemine (MSI-1436)
Description: A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trodusquemine (MSI-1436)
Description: A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trodusquemine (MSI-1436)
Description: A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03946488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Description: Functional electrical stimulation of finger's muscles in order to open the hand
Study: NCT01198873

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronedarone
Description: Film-coated tablet~Oral administration under fed conditions (during breakfast and dinner)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Dronedarone)
Description: film-coated tablet strictly identical in appearance~Oral administration under fed conditions (during breakfast and dinner)
Study: NCT02004067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Restasis
Description: Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.
Study: NCT02629523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afatinib
Description: Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
Study: NCT01009996

Intervention type: PROCEDURE
Intervention: Kissing DEB
Description: Provisional bare metal stenting followed by kissing drug-eluting balloons
Study: NCT02209233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Massage Therapy
Study: NCT02761928

Intervention type: OTHER
Intervention: Beighton score for hypermobility
Description: The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.

Intervention type: OTHER
Intervention: Beighton score for hypermobility
Description: The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.

Intervention type: OTHER
Intervention: Beighton score for hypermobility
Description: The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.

Intervention type: OTHER
Intervention: Beighton score for hypermobility
Description: The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.
Study: NCT02004067

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Refresh Endura
Description: Refresh Endura is a topical lubricant produced by Allergan, Inc.
Study: NCT02199119

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 min of moderate exercise on a treadmill

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: 30 min of moderate exercise on a treadmill

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV viewing
Description: watching TV (animated children's programming) for 30 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TV viewing
Description: watching TV (animated children's programming) for 30 min

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sitting quietly
Description: Sitting quietly for 30 min
Study: NCT02816424

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teens Exploring and Managing Prevention Options (TEMPO)
Study: NCT02761928

Intervention type: OTHER
Intervention: Beighton score for hypermobility
Description: The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.

Intervention type: OTHER
Intervention: Beighton score for hypermobility
Description: The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.

Intervention type: OTHER
Intervention: Beighton score for hypermobility
Description: The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.

Intervention type: OTHER
Intervention: Beighton score for hypermobility
Description: The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.

Intervention type: OTHER
Intervention: Beighton score for hypermobility
Description: The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.

Intervention type: OTHER
Intervention: Beighton score for hypermobility
Description: The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.